Ibrutinib-associated oral ulcers

Oral Oncol. 2020 Jan:100:104445. doi: 10.1016/j.oraloncology.2019.104445. Epub 2019 Oct 17.

Authors

Grigorios Thermos¹, Konstantinos I Tosios²

Affiliations

¹ Department of Oral Medicine and Pathology, School of Dentistry, National and Kapodistrian University of Athens, 2 Thivon Street, 11527 Athens, Greece. Electronic address: gthermos@dent.uoa.gr.
² Department of Oral Medicine and Pathology, School of Dentistry, National and Kapodistrian University of Athens, 2 Thivon Street, 11527 Athens, Greece. Electronic address: ktosios@dent.uoa.gr.

PMID: 31629661
DOI: 10.1016/j.oraloncology.2019.104445

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Aged
Combined Modality Therapy / methods*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Male
Metronidazole / administration & dosage
Metronidazole / therapeutic use
Mouthwashes
Oral Ulcer / chemically induced
Oral Ulcer / diagnosis*
Oral Ulcer / drug therapy
Piperidines
Prednisolone / administration & dosage
Prednisolone / therapeutic use
Pyrazoles / administration & dosage
Pyrazoles / adverse effects*
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*
Treatment Outcome

Substances

Mouthwashes
Piperidines
Pyrazoles
Pyrimidines
Metronidazole
ibrutinib
Prednisolone
Adenine